Stocks · News reference
Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% to
JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $165.
Eight sectors are higher and three are lower in Monday's regular session, with growth, cyclical and defensive sectors split across the top three positions. The leaders are separated rather than clustered.
U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
U.S. stock futures rose, while Goosehead fell after a downgrade; NFT, Armada and other stocks also slid in premarket trading.